Last $2.21 USD
Change Today -0.13 / -5.56%
Volume 24.0K
UPI On Other Exchanges
As of 8:10 PM 10/17/14 All times are local (Market data is delayed by at least 15 minutes).

uroplasty inc (UPI) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/24/14 - $5.40
52 Week Low
10/10/14 - $2.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for UROPLASTY INC (UPI)

Related News

No related news articles were found.

uroplasty inc (UPI) Related Businessweek News

No Related Businessweek News Found

uroplasty inc (UPI) Details

Uroplasty, Inc., a medical device company, develops, manufactures, and markets products for the treatment of voiding dysfunctions primarily in the United States. It principally offers Urgent PC Neuromodulation system, a minimally-invasive, neuromodulation system that delivers percutaneous tibial nerve stimulation for office-based treatment of overactive bladder and the associated symptoms of urinary urgency, urinary frequency, and urge incontinence. The company also provides Macroplastique implants, an injectable and urethral bulking agent for the treatment of adult female stress urinary incontinence due to intrinsic sphincter deficiency, as well as for the treatment of male stress incontinence, fecal incontinence, vocal cord rehabilitation, and vesicoureteral reflux. In addition, it offers Macroplastique products for treatment of vesicoureteral reflux; Urgent PC System for the treatment of fecal incontinence; PTQ Implants, which provides a minimally-invasive, soft-textured permanent implant for treatment of fecal incontinence; and VOX Implants, a silicone elastomer bulking material for vocal cord rehabilitation applications, as well as distributes wound care products. The company sells its products primarily to urologists, urogynecologists, and gynecologists through a direct sales organization in the United Kingdom, the Netherlands, Switzerland, and the Nordic countries, as well as through distributors in other markets. Uroplasty, Inc. was incorporated in 1992 and is headquartered in Minnetonka, Minnesota.

113 Employees
Last Reported Date: 06/9/14
Founded in 1992

uroplasty inc (UPI) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $589.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $212.7K
Vice President of Corporate Development
Total Annual Compensation: $195.1K
Senior Vice President of Global Sales and Mar...
Total Annual Compensation: $332.3K
Compensation as of Fiscal Year 2014.

uroplasty inc (UPI) Key Developments

Uroplasty, Inc. Announces Board Changes, Effective from October 15, 2014

Uroplasty, Inc. announced that Kenneth H. Paulus has been appointed to the Company's Board of Directors effective October 15, 2014. Mr. Paulus will chair the Board's compensation committee and serve on the nominating committee. Mr. Paulus currently serves as Chief Executive Officer of Allina Heath. Before joining Allina Health in 2005, Mr. Paulus was President and Chief Executive Officer of HealthOne Care System. Mr. Paulus currently serves on the Board of Overseers for the University of Minnesota Carlson School of Business, is a trustee with Hamline University, and serves on the executive committee and board of directors for the Minnesota Hospital Association. Uroplasty also reported that Tom Jamison and Lee Jones have resigned from the Board of Directors, effective October 15, 2014.

Uroplasty, Inc. Presents at Craig-Hallum Capital Group's 5th Annual Alpha Select Conference, Sep-18-2014 12:00 PM

Uroplasty, Inc. Presents at Craig-Hallum Capital Group's 5th Annual Alpha Select Conference, Sep-18-2014 12:00 PM. Venue: Convene Midtown East, 730 3rd Avenue, 17th Floor, New York, New York, United States. Speakers: Brett A. Reynolds, Chief Financial Officer, Principal Accounting Officer, Senior Vice President and Secretary, Darin Hammers, Senior Vice President of Global Sales and Marketing.

Uroplasty, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2014; Reaffirms Earnings Guidance for the Full Year of Fiscal 2015

Uroplasty, Inc. reported unaudited consolidated earnings results for the first quarter ended June 30, 2014. For the quarter, the company's net sales were $6,384,629 compared to $5,840,841 a year ago. Operating loss was $2,174,441 compared to $1,601,686 a year ago. Loss before income taxes was $2,170,518 compared to $1,595,117 a year ago. Net loss was $2,190,332 compared to $1,609,292 a year ago. Basic and diluted net loss per common share was $0.10 compared to $0.08 a year ago. Net cash used in operating activities was $1,505,465 compared to $685,094 a year ago. Purchases of property, plant and equipment was $52,739 compared to $189,789 a year ago. Non GAAP operating loss was $1,778,000 compared to $1,499,000 a year ago. For the full-year fiscal 2015 the company continues to expect revenue growth in the range of 9% to 12%, approximately 15% growth in global Urgent PC sales, and slightly higher gross margins on a year-over-year basis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
UPI:US $2.21 USD -0.13

UPI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bacterin International Holdings Inc $4.02 USD +0.06
Cytori Therapeutics Inc $0.51 USD -0.0035
Stereotaxis Inc $1.88 USD -0.04
Urologix Inc $0.10 USD -0.0025
Vision Sciences Inc/DE $0.89 USD -0.0399
View Industry Companies

Industry Analysis


Industry Average

Valuation UPI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.9x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UROPLASTY INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at